Phase I dose-escalation study of milciclib in combination with gemcitabine in patients with refractory solid tumors
ConclusionThe combination treatment was well tolerated with manageable toxicities. The recommended phase II dose was 80 mg/m2/day for milciclib and 1000 mg/m2/day for gemcitabine. This combination treatment regimen showed encouraging clinical benefit in ~36% patients, including gemcitabine refractory patients. These results support further development of combination therapies with milciclib in advanced cancer patients.
Source: Cancer Chemotherapy and Pharmacology - Category: Cancer & Oncology Source Type: research
More News: Asbestosis | Ataxia | Cancer | Cancer & Oncology | Carcinoma | Chemotherapy | Drugs & Pharmacology | Mesothelioma | Non-Small Cell Lung Cancer | Pancreas | Pancreatic Cancer | Study | Thrombocytopenia | Thyroid | Thyroid Cancer | Toxicology